Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.69 CAD | +1.22% |
|
-2.04% | -8.73% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.73% | 5.31B | - | ||
-5.81% | 180B | C+ | ||
-1.63% | 106B | C | ||
-4.14% | 67.55B | A | ||
-6.56% | 46.11B | B- | ||
+13.22% | 45.79B | B- | ||
+2.58% | 41.61B | B+ | ||
+19.93% | 31.07B | B | ||
+11.40% | 24.77B | A- | ||
-5.36% | 24.27B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BLCO Stock
- BLCO Stock
- Ratings Bausch + Lomb Corporation